Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer

Wei Tao; Weiqi Wang; Jingfang Zhai; Linlin Guo

doi:10.12659/MSM.940545

08 December 2023: Clinical Research

Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer

Wei Tao ^1DEF* , Weiqi Wang ^1CDF , Jingfang Zhai ^2BCF , Linlin Guo ^1ABF

DOI: 10.12659/MSM.940545

Med Sci Monit 2023; 29:e940545

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 5 Overall survival between patients sensitive to neoadjuvant chemotherapy and patients insensitive to neoadjuvant chemotherapy. Overall survival: survival of patients from detection of disease to death after adjuvant chemotherapy by any cause. χ2 test was used for statistical analysis.

Back to the Article

Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer

Your Privacy